TLR7: A promising drug target for lupus

As we celebrate World MS Day on 30th May 2023, it’s a great opportunity to reflect on the significant strides that have been made in MS research over the past 5 years.

Causaly cofounders Yiannis Kiachopoulos and Artur Saudabayev hosted a webinar, “From AI to Impact”, in April 2023, exploring the transformative power of AI and GPT applications in early drug discovery. During this captivating session, they demonstrated how Causaly combines visual evidence with high precision knowledge graphs to answer complex research questions in mechanistic biology. 

Two targets were chosen for their novelty – transcription factor CEBPB and transport protein MX2, both reported to be associated to Lupus in 2022.

Toll-like receptor 7 (TLR7) has long been implicated in lupus. Now scientists are uncovering precisely how. 

Lupus is an autoimmune disease which affects about 1 in 1000 people, which commonly causes joint pain, skin rashes and tiredness. Treatment options are improving for patients with lupus, and the target discovery landscape is heating up.